ZA907492B - Stabilized aqueous formulations of small peptides - Google Patents

Stabilized aqueous formulations of small peptides

Info

Publication number
ZA907492B
ZA907492B ZA907492A ZA907492A ZA907492B ZA 907492 B ZA907492 B ZA 907492B ZA 907492 A ZA907492 A ZA 907492A ZA 907492 A ZA907492 A ZA 907492A ZA 907492 B ZA907492 B ZA 907492B
Authority
ZA
South Africa
Prior art keywords
small peptides
aqueous formulations
stabilized aqueous
stabilized
formulations
Prior art date
Application number
ZA907492A
Other languages
English (en)
Inventor
Gideon Goldstein
Goldstein Gideon
Tapan Audhya
Audhya Tapan
Original Assignee
Immunobiology Res Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Res Inst Inc filed Critical Immunobiology Res Inst Inc
Publication of ZA907492B publication Critical patent/ZA907492B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA907492A 1989-09-28 1990-09-19 Stabilized aqueous formulations of small peptides ZA907492B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41384189A 1989-09-28 1989-09-28

Publications (1)

Publication Number Publication Date
ZA907492B true ZA907492B (en) 1991-10-30

Family

ID=23638883

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA907492A ZA907492B (en) 1989-09-28 1990-09-19 Stabilized aqueous formulations of small peptides

Country Status (14)

Country Link
EP (1) EP0420649A3 (fr)
JP (1) JPH04502017A (fr)
AU (1) AU6446790A (fr)
BR (1) BR9006934A (fr)
CA (1) CA2026149A1 (fr)
DD (1) DD298053A5 (fr)
HU (1) HUT59013A (fr)
IE (1) IE903475A1 (fr)
IL (1) IL95663A0 (fr)
IT (1) IT1240314B (fr)
NZ (1) NZ235324A (fr)
PT (1) PT95451A (fr)
WO (1) WO1991004743A1 (fr)
ZA (1) ZA907492B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036050A (en) * 1989-01-12 1991-07-30 Immunobiology Research Institute, Inc. Compositions containing thymopentin for topical treatment of skin disorders
ATE249234T1 (de) * 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
CA2192725C (fr) 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005012347A2 (fr) 2003-08-05 2005-02-10 Novo Nordisk A/S Nouveaux derives de l'insuline
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
HRP20200512T2 (hr) 2008-08-15 2024-05-24 Ironwood Pharmaceuticals, Inc. Formulacije koje sadrže linaklotid za oralnu primjenu
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US8329649B2 (en) * 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
CA2770077A1 (fr) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
ES2638589T3 (es) 2010-02-17 2017-10-23 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos intestinales
JP5921545B2 (ja) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの安定な製剤
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
JP5996631B2 (ja) 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
LT2768525T (lt) 2011-10-18 2019-09-25 Coherus Biosciences, Inc. Etanercepto kompozicijos, stabilizuotos magnio jonais
JP2015533797A (ja) 2012-09-11 2015-11-26 コヒラス・バイオサイエンシズ・インコーポレイテッド 高純度および優れた収率の正確に折り畳まれたエタネルセプト
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105012232B (zh) * 2015-08-14 2017-09-05 北京世桥生物制药有限公司 一种胸腺五肽注射液及其制作方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2023017537A1 (fr) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Composition peptidique orale perméable au tractus gastro-intestinal à base d'huile algale

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190646A (en) * 1975-11-11 1980-02-26 Sloan-Kettering Institute For Cancer Research Polypeptide compositions and methods
JPS57169425A (en) * 1981-04-10 1982-10-19 Eisai Co Ltd Composition and method for preventing adsorption of secretin
EP0082481B2 (fr) * 1981-12-23 1990-09-12 Schering Corporation Compositions stabilisées d'interféron alpha et leur préparation
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4749690A (en) * 1986-01-27 1988-06-07 Ortho Pharmaceutical Corporation Treatment of allergy with thymopentin
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator

Also Published As

Publication number Publication date
BR9006934A (pt) 1991-10-22
JPH04502017A (ja) 1992-04-09
WO1991004743A1 (fr) 1991-04-18
IT9019421A1 (it) 1991-03-29
IL95663A0 (en) 1991-06-30
HU907939D0 (en) 1991-08-28
HUT59013A (en) 1992-04-28
IT9019421A0 (it) 1990-02-20
EP0420649A2 (fr) 1991-04-03
NZ235324A (en) 1992-07-28
IE903475A1 (en) 1991-04-10
IT1240314B (it) 1993-12-07
PT95451A (pt) 1991-05-22
EP0420649A3 (en) 1991-07-31
DD298053A5 (de) 1992-02-06
AU6446790A (en) 1991-04-28
CA2026149A1 (fr) 1991-03-29

Similar Documents

Publication Publication Date Title
HU907939D0 (en) Stabilized aqueous formulations of small peptides
HUP0000589A3 (en) Aqueous formulations of peptides
HU9201966D0 (en) An improved vaccine of meningococcus-polysaccharide conjunction
EP0390930A4 (en) Stable aqueous preparation of active vitamin d 3?
GB8908250D0 (en) Formulations
IL96306A0 (en) Preparation of deoxyfluoronucleosides
SG47072A1 (en) Water-containing external preparations
AP9000174A0 (en) Antiparasitical formulations
EP0450100A4 (en) Physiologically active peptide
GB8619182D0 (en) Peptides & derivatives
GB8916391D0 (en) Preparation of polyacetals
IL95024A0 (en) Preparation of 2-diazo-3-trisubstituted silyloxy-3-butenoates
GB8918394D0 (en) Preparation of polyhemiacetals
IL89362A0 (en) Preparation of tetrabromotetralin
CS275222B2 (en) Analogues of deamino-vasopressin
GB8808440D0 (en) Preparation of peptide derivatives
IE894144L (en) Preparation of deglucoteicoplanin
IE892415L (en) Preparation of polyhydroxysilazanes
IE893752L (en) Preparation of n-acyl-aminomethyl-phosphonates
IE892537L (en) Preparation of trifluoroethanol.
NO911988D0 (no) Stabiliserte vandige formuleringer av smaa peptider.
IE890708L (en) Peptide equivalents of non-peptides
GB8619181D0 (en) Peptides & derivatives
GB8828413D0 (en) Ws7528 substance & preparation thereof
IE891038L (en) Peptide derivatives